Lexicon Pharmaceuticals (LXRX) Interest Expenses (2010 - 2023)

Lexicon Pharmaceuticals (LXRX) has 14 years of Interest Expenses data on file, last reported at $3.9 million in Q3 2023.

• Quarterly Interest Expenses rose 351.27% year-over-year to $3.9 million in Q3 2023, while the trailing twelve-month figure through Jun 2024 was $3.9 million (down 32.17% YoY) and the FY2022 annual result came in at $2.8 million, up 246.63% from the prior year.
• Interest Expenses improved to $3.9 million in Q3 2023 per LXRX's latest filing, from $2.0 million in the prior quarter.
• Across five years, Interest Expenses topped out at $5.2 million in Q3 2019 and bottomed at $110000.0 in Q1 2022.
• The 5-year median for Interest Expenses is $1.8 million (2023), against an average of $2.4 million.
• The widest annual swing landed in 2021, when Interest Expenses slumped 96.75%; it then surged 1555.45% in 2023.
• Tracing LXRX's Interest Expenses over 5 years: stood at $5.2 million in 2019, then plunged by 96.73% to $170000.0 in 2020, then soared by 73.53% to $295000.0 in 2021, then surged by 273.9% to $1.1 million in 2022, then soared by 253.49% to $3.9 million in 2023.
• Per Business Quant, the three latest LXRX Interest Expenses figures stand at $3.9 million (Q3 2023), $2.0 million (Q2 2023), and $1.8 million (Q1 2023).

Peer Comparison